Media headlines about Theravance Biopharma (NASDAQ:TBPH) have trended somewhat positive on Tuesday, according to Accern Sentiment. Accern rates the sentiment of news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Theravance Biopharma earned a news sentiment score of 0.11 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 45.3911621445023 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Theravance Biopharma traded up $0.85, reaching $23.68, during trading on Tuesday, Marketbeat.com reports. 63,111 shares of the stock were exchanged, compared to its average volume of 236,054. Theravance Biopharma has a twelve month low of $21.27 and a twelve month high of $42.61. The company has a debt-to-equity ratio of 3.53, a quick ratio of 4.08 and a current ratio of 4.25. The company has a market cap of $1.24 billion, a P/E ratio of -4.34 and a beta of 1.81.
Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($1.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.26) by $0.04. Theravance Biopharma had a negative return on equity of 188.96% and a negative net margin of 1,383.47%. The business had revenue of $8.32 million for the quarter, compared to the consensus estimate of $5.74 million. equities analysts predict that Theravance Biopharma will post -4.8 earnings per share for the current year.
A number of brokerages have recently issued reports on TBPH. ValuEngine downgraded Theravance Biopharma from a “hold” rating to a “sell” rating in a research note on Wednesday, March 7th. BidaskClub downgraded Theravance Biopharma from a “sell” rating to a “strong sell” rating in a research note on Tuesday, March 20th. Needham & Company LLC reissued a “buy” rating and issued a $40.00 price objective on shares of Theravance Biopharma in a research note on Wednesday, May 9th. Leerink Swann set a $31.00 price objective on Theravance Biopharma and gave the company a “buy” rating in a research note on Wednesday, May 9th. Finally, Cantor Fitzgerald set a $55.00 price target on Theravance Biopharma and gave the stock a “buy” rating in a research note on Tuesday, May 8th. Three research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $39.29.
In related news, EVP Bradford J. Shafer sold 14,040 shares of the company’s stock in a transaction that occurred on Friday, June 8th. The stock was sold at an average price of $23.97, for a total transaction of $336,538.80. Following the transaction, the executive vice president now directly owns 133,324 shares of the company’s stock, valued at approximately $3,195,776.28. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Bradford J. Shafer sold 10,140 shares of the company’s stock in a transaction that occurred on Wednesday, June 6th. The stock was sold at an average price of $24.09, for a total value of $244,272.60. Following the transaction, the executive vice president now directly owns 133,324 shares in the company, valued at $3,211,775.16. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 34,180 shares of company stock worth $823,711. 6.90% of the stock is owned by company insiders.
Theravance Biopharma Company Profile
Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria.
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.